Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Companies are developing myostatin inhibitors for GLP-1RA- related muscle loss, but some experts doubt their necessity.

Drug companies are also testing whether blocking myostatin can help preserve muscle in people using GLP-1 receptor weight loss drugs, such as Ozempic, which can lead to both fat and muscle loss.

Filed two patent applications for lead candidate EL-22, covering muscle loss in obese patients as a monotherapy and in combination with GLP-1 receptor agonists Elevai Biosciences patent portfolio ...

San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin antibody that it hopes can induce weight loss while retaining muscle ...

EL-22, a first-in-class myostatin asset, is being developed as a potential combination therapy with GLP-1 receptor agonists for obesity. It aims to address muscle loss, a common side effect of ...

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations ...

iBio in-licenses a novel anti-myostatin antibody, IBIO-600, to enhance cardiometabolic and obesity treatment development.

EL-22 is leveraging a myostatin-engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.

GLP-1 receptor agonists have taken the food industry by storm. Now a new generation is in the works.